UTHR
United Therapeutics Corporation
Is UTHR Halal?
Biotechnology for pulmonary diseases with excellent compliance.
What You Should Know
United Therapeutics develops therapies for pulmonary arterial hypertension and other conditions. Its March 31, 2026 Form 10-Q reports $6,714.2 million of assets, no reported interest-bearing debt, $1,279.7 million of cash, $2,191.4 million of marketable investments, $312.0 million of receivables and $781.5 million of quarterly revenue. Liquidity/assets is 51.72%, above the examined FTSE, MSCI and Malaysia limits, and disclosed interest income is 5.35% of revenue; the core therapeutic business remains generally permissible but the quantitative screen fails.
⚠️ Concerns
- •Marketable investments exceed examined liquidity limits
- •Interest income exceeds the examined FTSE 5% proxy
- •Xenotransplantation and animal-research ethics
- •Clinical-trial and patient end uses
Current quantitative Sharia screen
Based on 10-Q figures for the period ended 2026-03-31; calculated 2026-07-15.
0 / 6,714.2
3,471.1 / 6,714.2
1,591.7 / 6,714.2
41.8 / 781.5
- Financial
- Fails
- Overall
- Fails
Debt/assets is 0.00%, but liquidity/assets is 51.72%, above the examined FTSE 33.333% limit; receivables-plus-cash/assets is 23.72% and disclosed interest income is 5.35% of revenue, above the examined 5% income limit.
- Financial
- Fails
- Overall
- Fails
Liquidity/assets is 51.72%, above the examined MSCI 33.33% total-assets limit; debt and receivables-plus-cash remain below their examined limits.
- Financial
- Fails
- Overall
- Fails
Liquidity/assets is 51.72%, above the examined Malaysia 33% limit; this is a calculation against the named ratios, not an official classification.
- Financial
- Not calculated
- Overall
- Fails
A licensed historical market-cap series is not stored; the liquidity screen fails independently.
Business-activity disclosure
United Therapeutics develops pulmonary therapies and biotechnology programs, including xenotransplantation research. The core therapeutic activity is generally permissible.
Limitation: The filing does not allocate every research, animal-source, transplant or patient end use into a scholar-approved prohibited-revenue numerator.
Purification
United Therapeutics discloses $41.8 million of interest income but does not provide a scholar-approved purification percentage or separate prohibited-activity numerator.
Inputs, assumptions and primary sources
- Amounts are USD millions from United Therapeutics' March 31, 2026 Form 10-Q.
- No interest-bearing debt is reported in the selected balance-sheet captions; operating leases and ordinary liabilities are excluded.
- Cash is $1,279.7 million. Current and non-current marketable investments total $2,191.4 million and are used as the interest-bearing-securities proxy.
- Accounts receivable are $312.0 million; first-quarter total revenues are $781.5 million.
- Disclosed interest income is $41.8 million.
- Pulmonary therapies and related biotechnology are generally permissible; xenotransplantation, animal research and patient end uses require continuing qualitative review.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Similar Stocks
Want to screen more assets?
Use our interactive Halal Checker to screen any stock, ETF, or crypto instantly.
Go to Halal Checker →